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OBJECTIVE—To identify metabolic derangements contributing
to diabetes susceptibility in the leptin receptor–deﬁcient obese
C57BLKS/J-db/db (BKS-db) mouse strain.
RESEARCH DESIGN AND METHODS—Young BKS-db mice
were used to identify metabolic pathways contributing to the
development of diabetes. Using the diabetes-resistant B6-db
strain as a comparison, in vivo and in vitro approaches were
applied to identify metabolic and molecular differences between
the two strains.
RESULTS—Despite higher plasma insulin levels, BKS-db mice
exhibit lower lipogenic gene expression, rate of lipogenesis,
hepatic triglyceride and glycogen content, and impaired insulin
suppression of gluconeogenic genes. Hepatic insulin receptor
substrate (IRS)-1 and IRS-2 expression and insulin-stimulated
Akt-phosphorylation are decreased in BKS-db primary hepato-
cytes. Hyperinsulinemic-euglycemic clamp studies indicate that
in contrast to hepatic insulin resistance, skeletal muscle is more
insulin sensitive in BKS-db than in B6-db mice. We also demon-
strate that elevated plasma triglyceride levels in BKS-db mice are
associated with reduced triglyceride clearance due to lower
lipase activities.
CONCLUSIONS—Our study demonstrates the presence of met-
abolic derangements in BKS-db before the onset of -cell failure
and identiﬁes early hepatic insulin resistance as a component of
the BKS-db phenotype. We propose that defects in hepatic insulin
signaling contribute to the development of diabetes in the
BKS-db mouse strain. Diabetes 59:1616–1625, 2010
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stablished in the 1940s, the C57BLKS (BKS)
inbred mouse strain represents one of the ﬁrst
animal models of type 2 diabetes (1). Develop-
ment of diabetes in these mice captures several
aspects of the human disease (2,3). First, diabetes in this
model is associated with obesity. Whereas lean BKS mice
are normoglycemic throughout their life, obese leptin-
deﬁcient (BKS-ob) or leptin receptor–deﬁcient (BKS-db)
mice develop severe hyperglycemia. Second, the natural
history of diabetes in BKS-ob or BKS-db is reminiscent of
the human disease. These mice initially compensate for
obesity-associated insulin resistance by increasing plasma
insulin levels, but exhibit -cell failure and insulin deﬁ-
ciency later in life. Finally, similarly to humans, diabetes in
BKS-db is determined by multiple genetic factors (4,5).
Despite extensive genetic analysis, the genes responsible
for diabetes susceptibility in the BKS strain remain to be
identiﬁed (6–8).
Early studies on BKS-db mice indicated that the devel-
opment of diabetes is associated with progressive -cell
degranulation and a precipitous decrease in -cell mass
and plasma insulin levels (2). In vivo radio-labeling studies
revealed that after an initial phase of hyperproliferation at
4–6 weeks of age, the replication of -cells gradually
decreases despite increasing glucose levels (9). In contrast
to BKS, introduction of the db mutation into the C57BL/6J
(B6) genetic background produces a dramatically different
-cell phenotype (2,4). Although similarly obese as BKS-
db, B6-db mice compensate for insulin resistance by -cell
hyperplasia, increased islet mass, and hyperinsulinemia
and maintain only mildly elevated blood glucose levels
throughout their life. The markedly different -cell re-
sponses to obesity in BKS-db and B6-db mice suggest that
genetically determined variation in -cell viability/survival
in the face of chronic glycemic stress is responsible for
differences in diabetes susceptibility between the two
strains. Consistent with this hypothesis, BKS -cells are
more sensitive than B6 to cell death triggered by -cell
toxins, such as alloxan and streptozotocin (10–12), and
glucose-stimulated islet cell replication is diminished in
BKS (13). In conclusion, previous studies suggest that
variant -cell functions underlie the differences in diabetes
susceptibility between BKS-db and B6-db mice.
In the current study, we reﬁne the current -cell–centric
model of diabetes susceptibility in BKS-db by demonstrat-
ing metabolic defects preceding the onset of -cell failure.
In particular, BKS-db mice exhibit elevated hepatic insulin
resistance associated with altered lipogenic and gluconeo-
genic pathways relative to B6-db. We propose that early
hepatic insulin resistance contributes to the development
of diabetes in the BKS-db strain.
RESEARCH DESIGN AND METHODS
Animals. C57BL/6J-db/db (B6-db) and C57BLKS/J-db/db (BKS-db) mice were
purchased from The Jackson Laboratory. Mice were maintained in the animal
care facilities of the University of California and VA Greater Los Angeles
Healthcare System on a 12-h light/dark cycle. The mice were maintained on a
standard diet (Harlan Teklad LM-485). Before all experiments, mice were
fasted for 4 h (9:00 A.M. to 1:00 P.M.) unless indicated otherwise. Protocols were
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Phenotypic characterization of mice. Plasma lipids, glucose, and insulin
were determined as described previously (14). The Luminex 100 system was
used to measure plasma leptin, resistin, tumor necrosis factor-, and inter-
leukin-6 levels. Adiponectin, corticosterone (R&D Systems, Minneapolis, MN),
and glucagon (ALPCO Diagnostics, Salem, NH) were determined by enzyme-
linked immunosorbent assays. Hepatic glycogen content was assayed at the
Mouse Metabolic Phenotyping Center at Yale University. Hepatic triglyceride
(TG) content was assayed using the L-type TG H kit (Wako Diagnostics,
Richmond, VA) with modiﬁcations. Brieﬂy, liver tissue was homogenized in
ice-cold PBS with a Polytron homogenizer. After Folch extraction, samples
were centrifuged and the lower (organic) phase was transferred to new tubes.
The organic volume was dried in vacuum and re-dissolved in 90 l of 10%
Triton X-100 in isopropanol by vortexing. After the addition of 1.5 ml Wako
Reagent A, samples were vortexed and incubated at 37° C for 5 min. Samples
were vortexed until clear and 0.75 ml Wako Reagent B was added followed by
incubation at 37°C for 30 min. Samples were vortexed again until clear and
then put on ice until measurement of optical density at 600 nm. A calibration
curve was established using the Wako Lipid Calibrator.
Assays of lipid metabolism. Fatty acid (FA) synthesis and oxidation were
measured in liver slice cultures (15).
FA oxidation. After an overnight fast, mice were anesthetized with isoﬂurane
and killed by cervical dislocation. The left caudal lobe of the liver was rapidly
excised, and fresh liver sections of uniform thickness (1 mm, averaging 60
mg) were obtained using a Stadie-Riggs microtome. The liver sections were
weighed and immediately incubated at 37°C for 40 min in Krebs-Henseleit
buffer under 95% O2:5% CO2 that contained 5.5 mmol/l glucose, 3% BSA, 1
mmol/l oleate, and [
14C-U]-palmitic acid (2.5 Ci/ml). The average time from
euthanizing the animals to getting the liver section into the buffer was 2 min.
Rates of FA oxidation were assessed by determining
14CO2 trapped in hyamine
hydroxide saturated ﬁlter paper as described previously (16).
Hepatic lipogenesis. Liver sections were obtained and incubated essentially
as described above, except that
3H2O (0.5 mCi/vessel) was used as the
radioactive tracer and incubations were carried out for 1 h (17). Media and
tissue were then collected and total lipids extracted as described above. Total
lipid isolates were then hydrolyzed in an acid/acetonitrile solution as de-
scribed previously (18), and the lipids were re-extracted and dried under
nitrogen and radioactivity in the fatty acid fraction determined by liquid
scintillation spectrometry.
Hepatic TG secretion. TG secretion was determined by comparing plasma
TG levels at 0 and 30 min after intravenous injection of Triton WR1339
(Tyloxapol, Sigma Chemical) as described (19). Calculations assumed plasma
volume of 3.5% of body weight.
Triglyceride clearance. Clearance of TG (10 l peanut oil/g body weight
delivered by gavage) was determined by following plasma TG levels at hourly
intervals after the administration of lipid.
Post-heparin plasma. Ten units of heparin was administered by tail-vein
injection followed by retro-orbital blood collection 10 min later as described
(20). Plasma lipase activities were determined as described below.
Gene expression. Total RNA was isolated with Trizol (Invitrogen) and
reverse transcribed using the Omniscript RT kit (Qiagen). Quantitative
real-time RT-PCR was performed as described previously (21) using primers
shown in supplementary Table 1, available in an online appendix at http://
diabetes.diabetesjournals.org/cgi/content/full/db09-0878/DC1. Each sample
was measured in triplicates. Expression of the TATA-box binding protein
(Tbp) and hypoxanthine guanine phosphorybosyl transferase (Hprt) genes
were used for normalization.
Hyperinsulinemic-euglycemic clamp. Euglycemic clamps were performed
in conscious 1-month-old mice using a 10 mU/kg/min insulin dose as described
(22).
Insulin signaling in primary hepatocytes. Hepatocytes were isolated by a
two-step perfusion protocol that is based on minor modiﬁcations of the
method described by Seglen (23). Brieﬂy, mice were anesthetized by intra-
peritoneal injection of pentobarbital (50 mg/kg). The abdominal cavity was
opened and the liver perfused via the portal vein ﬁrst with a Ca
2 Mg
 free
EDTA chelating solution, followed by perfusion with a Ca
2 Mg
 replete
buffer containing type I collagenase (Worthington Biochemical, Lakewood,
NJ). The hepatocytes were then dissociated by cutting the liver capsule and
gently shaking in the collagenase solution. A series of ﬁve low-speed (50g)
centrifugations were performed to wash and differentially sediment hepato-
cytes from other cell types, particularly Kupffer and endothelial cells. The
resulting cell pellet was re-suspended, and an aliquot was taken to determine
cell number and viability by trypan blue exclusion. The cells were plated at a
density of 2.0  10
6 cells on 60-mm collagen-coated plates (BD Biosciences,
San Jose, CA) in hepto-stim media (BD Biosciences, San Jose, CA) containing
10% FBS (ATCC, Manassas, VA) and supplemented with pen/strep (ATCC,
Manassas, VA) and fungizone (Invitrogen, Carlsbad, CA) and allowed to
adhere for 4 h. The media were then removed, the cells washed once with
PBS, and fresh media added. The following day, the media were changed and
replaced with the same media except without the fungizone. After 24 h in
culture, cells were serum-starved overnight in 199 medium supplemented with
glutamine, NaHCO3, and pen/strep. After incubation in fresh serum-free media
for 2 h, cells were stimulated with 100 nmol/l of porcine insulin for 10 min in
triplicate wells. Cells were solubilized in lysis buffer (50 mmol/l Tris-HCl, pH
7.5, 150 mmol/l NaCl, 1% NP-40) containing inhibitors of proteases (Complete
Mini; Roche, Indianapolis, IN) and phosphatases (PhosStop; Roche). Protein
concentration was determined by the BCA assay (Pierce, Rockford, IL).
Immunoblot analysis. Tissue and cell lysates were analyzed with Western
blotting. Primary antibodies against insulin receptor substrate (IRS)-1 (1:500
dilution, Upstate Biotechnology, Lake Placid, NY), IRS-2 (1:2,000 dilution,
Upstate), Akt (1:5,000 dilution, Cell Signaling Technologies, Danvers, MA),
and phospho-Akt (1:1,000 dilution, CST) were used followed by goat anti-
rabbit–horseradish peroxidase (1:10,000 dilution; Jackson ImmunoResearch,
West Grove, PA) secondary antibody. Blots were visualized using the ECL
chemiluminescent detection system (Roche).
Lipase assays. The activity of lipoprotein lipase (LPL) and hepatic lipase was
measured using the respective triolein substrates prepared by sonication (24).
To discriminate between LPL and hepatic lipase activities further, we took
advantage of the difference in salt sensitivity between these lipases. Lipase
activities were measured using the LPL substrate in the presence and absence
of 1 mol/l NaCl; LPL activity was calculated as the salt-inhibited fraction.
Tissues were homogenized in 25 mmol/l Tris-HCl, pH 7.5, containing 10%
glycerol, 0.2% deoxycholic acid (sodium salt), and 10 /ml heparin. Homoge-
nization (100 mg/ml) was carried out for 30 s on ice, using a Tekmar tissue
homogenizer, followed by centrifugation for 10 min at 10,000g to remove
insoluble debris and, in the case of adipose tissue, to separate the ﬂoating lipid
layer from the lysate.
Statistical analysis. Data are presented as mean  SE. Differences between
two groups were considered statistically signiﬁcant at P  0.05 using Student’s
t test. ANOVA was used for multiple group comparisons followed by Bonfer-
roni’s post hoc test, as implemented in the SigmaPlot software package
(Systat Software, San Jose, CA). Non-normally distributed trait values were
transformed before analysis as indicated.
RESULTS
Metabolic differences between young BKS-db and
B6-db mice. To characterize the development of diabetes
in the BKS-db strain, we performed a metabolic time-
course study (Fig. 1, line graphs, and supplementary Table
3). B6-db mice were used as controls, because they are
diabetes resistant despite their genetic similarity to BKS-
db. Consistent with previous reports (2,4), BKS-db and
B6-db mice exhibited similar body weights and adiposity,
with the exception of male BKS-db, which started losing
weight at 3 months because of severe diabetes (Fig. 1A and
B). Despite similar degrees of obesity, BKS-db and B6-db
mice displayed dramatic differences in glucose homeosta-
sis. B6-db mice compensated for insulin resistance associ-
ated with obesity by sharply increasing plasma insulin
levels (Fig. 1D). In contrast, insulin levels in BKS-db
gradually declined and were associated with progressive
hyperglycemia (Fig. 1C). These data are consistent with
previous studies implicating impaired -cell viability in
BKS-db as the primary determinant of diabetes suscepti-
bility (10,11,13). However, our time-course study also
revealed metabolic differences between the strains at 1
month of age, before the onset of diabetes in BKS-db (Fig.
1, right panels). At this age, BKS-db mice maintained
similar glucose levels, but over twofold higher insulin
concentrations in comparison to B6-db mice (Fig. 1C and
D). Moreover, these mice exhibited elevated plasma TG
(Fig. 1E), but lower free fatty acid (Fig. 1F) and total and
HDL cholesterol levels (data not shown) relative to their
B6-db counterparts. To assess the effects of strain back-
ground and genetic interaction with the db mutation, we
also phenotyped lean B6 and BKS mice (supplementary
Table 2). Among the traits analyzed, only HDL cholesterol
R.C. DAVIS AND ASSOCIATES
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BKS mice, whereas total cholesterol, free fatty acid, and
glucose traits revealed signiﬁcant strain  db interactions.
In conclusion, our results indicate -cell–independent
metabolic derangements in BKS-db mice. To investigate
the role of different tissues in the early metabolic differ-
ences observed between B6-db and BKS-db, we further
characterized 1-month-old mice in subsequent studies.
Relative muscle insulin sensitivity in young BKS-db
mice. Differences in plasma insulin and lipid levels are
frequently associated with different insulin response in
different tissues. To directly investigate insulin sensitivity
in young BKS-db and B6-db mice, hyperinsulinemic-eugly-
cemic clamps were performed. Upon infusion with 2.5
mU/kg/min insulin, the two strains exhibited similar met-
abolic parameters (data not shown). However, administra-
tion of increased doses of insulin (10 mU/kg/min)
unexpectedly revealed elevated glucose infusion rate and
insulin-stimulated whole-body glucose turnover in BKS-db,
indicating better systemic insulin sensitivity in this strain
(Table 1). Consistent with these results, insulin-stimulated
glucose uptake in gastrocnemius muscle was also higher
in BKS-db mice, suggesting that muscle tissue is likely
responsible for their relative insulin sensitivity. In con-
trast, the clamp showed severe hepatic insulin resistance
in both strains. In fact, even high-dose insulin infusion
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FIG. 1. Phenotype of B6-db and BKS-db mice. Body weight (A), adiposity (B), blood glucose (C), plasma insulin (D), TG (E), and free fatty acids
(FFA) (F) are shown at 1, 3, and 7 months of age (left panels). F, B6-db males (n  10); f, B6-db females (n  11); E, BKS-db males (n  10);
, BKS-db females (n  7). Labels of statistical signiﬁcance have been omitted from the charts for clarity. Bar graphs (right panels) show data
at 1 month of age. *P < 0.05 for differences between strains.
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production in either strain. In conclusion, these data
indicate relative muscle insulin sensitivity in BKS-db, but
severe hepatic insulin resistance in both strains.
Reduced insulin signaling in BKS-db hepatocytes. As
insulin sensitivity in muscle is expected to protect against,
rather than contribute to, the diabetic phenotype of BKS-
db, we focused on liver metabolism in subsequent exper-
iments. To investigate hepatic insulin resistance, we
compared insulin signaling in the two strains. Immunoblot
analysis revealed lower levels of both IRS-1 and IRS-2
proteins in BKS-db liver, suggesting reduced proximal
insulin signaling in this strain (Fig. 2A). To conﬁrm this
prediction, we assessed downstream signaling in primary
hepatocytes treated with insulin. Consistent with reduced
IRS expression, insulin-stimulated Akt phosphorylation
was reduced by 50% in BKS-db hepatocytes (Fig. 2B).
These results indicate a higher degree of hepatic insulin
resistance in BKS-db mice.
Altered hepatic metabolism in young BKS-db mice.
Next, we investigated the metabolic consequences of
elevated hepatic insulin resistance in BKS-db. Upon visual
examination of internal organs, BKS-db livers appeared
darker than their B6-db counterparts (Fig. 3A), suggesting
reduced steatosis in the former. Indeed, despite higher
plasma insulin levels in BKS-db mice, hepatic TG content
was over threefold lower in this strain (Fig. 3B). Similarly,
hepatic glycogen content was also signiﬁcantly reduced in
BKS-db mice (Fig. 3E).
Because plasma free fatty acid levels are lower in
BKS-db mice, reduced hepatic TG content may reﬂect
reduced substrate delivery for TG biosynthesis. Alterna-
tively, metabolic differences intrinsic to liver may also
contribute to reduced steatosis in BKS-db mice. To dis-
criminate between these possibilities, we used short-term
in vitro liver slice cultures, which allow examination of
metabolic pathways under conditions of controlled sub-
strate delivery (15). We ﬁrst examined hepatic lipogenesis
by measuring the incorporation of radioactivity into de
novo synthesized FAs from
3H2O. Despite elevated plasma
insulin levels in vivo, the rate of hepatic lipogenesis was
signiﬁcantly lower in BKS-db liver slices (Fig. 3C), suggest-
ing intrinsic metabolic differences in hepatic lipid synthe-
sis between the strains. Hepatic FA oxidation was not
signiﬁcantly different between the two strains, although
there was a trend toward increased oxidation in BKS-db
(Fig. 3D). We also tested the potential involvement of
circulating factors in the observed metabolic differences
by measuring plasma levels of various adipokines and
hormones implicated in hepatic metabolism (25). Plasma
concentrations of adiponectin, leptin, resistin, corticoste-
rone, and glucagon were similar in B6-db and BKS-db mice
(supplementary Table 3). Taken together, our results
indicate altered lipid and carbohydrate metabolism con-
sistent with elevated hepatic insulin resistance in BKS-db
mice.
Altered hepatic gene expression in young BKS-db
mice. To determine if altered gene expression underlies
the metabolic differences observed between BKS-db and
B6-db mice, we measured mRNA levels of genes involved
in hepatic lipid and carbohydrate metabolism. Consistent
with reduced lipogenesis in BKS-db mice, expression
levels of all lipogenic genes tested (liver X receptor-
[LXR], sterol regulatory element binding protein-1c
[Srebp1c], peroxisome proliferator-activated receptor-	
[Ppar], acetyl-CoA carboxylase-1 [AccI], fatty acid syn-
thase [Fas], ATP citrate lyase [Acl], stearoyl-CoA desatu-
rase-1 [Scd1], and cytosolic malic enzyme [Me1]) were
signiﬁcantly lower in this strain (Fig. 4A). The expression
of enzymes involved in TG synthesis, including glycerol-3-
phosphate acyltransferase (Gpat) and lipin (Lpin1), was
also lower in BKS-db. As Srebp1c is a direct transcriptional
activator of lipogenic genes and Gpat (26), suppressed
Srebp1c expression is likely to be responsible for dimin-
ished hepatic lipid synthesis in BKS-db mice. Other targets
of Srebp1c, such as glucokinase (Gk) and the FA trans-
porter Cd36, also exhibited reduced expression in this
strain. In contrast, mRNA levels of acyl-CoA:diacylglycerol
acyltransferase-2 (Dgat2), a TG biosynthetic enzyme not
known to be regulated by Srebp1c, were similar in the two
strains.
We also analyzed gluconeogenic gene expression (Fig.
4B). After a 4-h fast, which results in more than twofold
higher insulin levels in BKS-db than in B6-db mice (Fig. 4B,
left panel), the mRNA levels of phosphoenopyruvate car-
boxykinase (Pepck), fructose-1,6-bisphosphatase (Fbp),
and glucose-6-phosphatase (G6p) were similar in the two
strains (Fig. 4B, right panel). Conversely, similar plasma
insulin levels after an overnight fast were associated with
elevated expression of Pepck and Fbp, but not G6p,i n
BKS-db mice (Fig. 4B). In conclusion, our gene expression
results indicate diminished hepatic insulin action in
BKS-db mice. Consistent with a proximal defect in insulin
signaling, hepatic insulin resistance affects both the lipogenic
and anti-gluconeogenic actions of insulin in this strain.
Reduced TG clearance in young BKS-db mice. BKS-db
mice exhibit twofold higher plasma TG levels than B6-db
mice at 1 month of age (Fig. 1E, right panel). Considering
the lower hepatic TG content in BKS-db mice (Fig. 3B),
this result was initially surprising. To investigate the
mechanisms underlying these differences, we measured
hepatic TG secretion in 1-month-old mice after inhibiting
clearance with Triton WR1339. This analysis indicated
similar rates of hepatic TG secretion in B6-db and BKS-db
mice (Fig. 5A). As plasma TG levels are determined by the
relative rates of secretion and clearance, we also mea-
TABLE 1
Hyperinsulinemic-euglycemic clamp measurements
B6-db BKS-db
n 86
Body weight (g) 22.1  0.5 22.5  0.7
Fat mass (g) 8.0  0.4 7.9  0.5
Lean mass (g) 12.6  0.4 12.5  0.5
Basal glucose (mg/dl) 125  10 116  19
Basal insulin (pmol/l) 328  63 324  53
Clamp glucose (mg/dl) 125  7 135  9
Clamp insulin (pmol/l) 1,882  136 1,829  258
Glucose infusion rate
(mg/kg/min) 7.2  0.9 21.3  2.8*
Whole-body glucose turnover
(mg/kg/min) 30.8  1.4 40.6  3.2†
Whole-body glycolysis
(mg/kg/min) 24.2  2.1 28.9  1.0
Whole-body glycogen synthesis
(mg/kg/min) 6.6  2.0 11.7  3.3
Muscle glucose uptake
(nmol/g/min) 162  20 314  46†
Suppression of hepatic glucose
production (%) 0 0
Data are means  SE. *P  0.0005; †P  0.05.
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B6-db mice, lipid ingestion resulted in a modest (less than
twofold) rise in plasma TG levels peaking at 2 h after
gavage and returning to baseline levels after 4 h (Fig. 5B).
In contrast, BKS-db mice exhibited an over fourfold in-
crease in TG at 2 h, and TG levels remained elevated
threefold after 4 h. These data indicate signiﬁcantly re-
duced clearance of circulating TG in BKS-db mice.
To test the potential role of lipases in reduced TG
clearance in BKS-db mice, we measured the activities of
these enzymes in postheparin plasma. Consistent with
reduced TG clearance, total lipase, LPL, and hepatic lipase
activities are signiﬁcantly lower in BKS-db plasma (Fig.
5C). To identify the tissue(s) responsible for differences in
LPL activity, we assayed lipase activity in isolated tissues
(Fig. 5D). Adipose and, to a smaller extent, heart from
BKS-db mice exhibit lower LPL activities, whereas skeletal
muscle shows the opposite pattern. In conclusion, these
data suggest that elevated plasma TG levels in BKS-db
mice result from reduced clearance primarily due to low
LPL activity in adipose. Further studies will be required to
explore the underlying mechanisms in this tissue.
DISCUSSION
Mutations in the leptin receptor gene cause severe obesity
and insulin resistance in rodents and humans (27–29). In
leptin receptor–deﬁcient (db mutation) mouse strains,
obesity is variably associated with hyperglycemia depend-
ing on genetic background (30). Diabetes-resistant strains,
such as B6-db, exhibit islet hypertrophy and insulin hyper-
secretion and are able to maintain mildly elevated plasma
glucose levels. In contrast, islets in the diabetes-suscepti-
ble BKS-db strain undergo atrophy leading to insulin
deﬁciency and hyperglycemia. The genes underlying these
phenotypic differences are largely unknown. Based on
reduced viability and proliferative capacity of BKS -cells
both in vivo and in vitro, diabetes susceptibility of this
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from individual animals. B: Insulin signaling in primary hepatocytes. Hepatocyte cultures were stimulated with 100 nmol/l insulin for 10 min.
Western blots show phosphorylated Akt (upper panel) and total Akt (lower panel). Graphs on the right represent densitometric analysis of band
intensities. *P < 0.05.
IMPAIRED HEPATIC METABOLISM IN C57BLKS-db MICE
1620 DIABETES, VOL. 59, JULY 2010 diabetes.diabetesjournals.orgstrain has been ascribed to genetic determinants acting in
islets (10–13). However, it is conceivable that genetic
differences manifested in other tissues may also contribute
to -cell failure through mechanisms that increase meta-
bolic stress on these cells (e.g., insulin resistance). Indeed,
in the current study, we demonstrate increased hepatic
insulin resistance in young BKS-db mice compared with
B6-db mice and propose that this metabolic abnormality
may lead to elevated -cell stress and the diabetic pheno-
type in BKS-db.
Side-by-side phenotypic characterization of BKS-db and
B6-db mice revealed differences in plasma lipid and insulin
levels as early as 1 month of age, even before the onset of
-cell dysfunction in BKS-db mice. These observations
indicated metabolic differences in tissues other than
-cells and prompted us to investigate the early BKS-db
phenotype further. Unexpectedly, hyperinsulinemic-eugly-
cemic clamp studies demonstrated higher whole-body and
muscle insulin sensitivity in BKS-db, indicating that this
tissue does not contribute to, but rather counteracts, the
diabetes-sensitive phenotype of this strain. However, the
clamp also revealed profound hepatic insulin resistance,
which completely abolished the effect of high doses of
insulin on hepatic glucose production in both strains.
However, in contrast to muscle, hepatic insulin resistance
is more severe in BKS-db than B6-db mice. Despite ele-
vated plasma insulin levels, BKS-db mice exhibit signs of
reduced hepatic insulin action including diminished lipo-
genesis, glycogen accumulation, insulin-stimulated gene
expression and TG secretion, and suppression of glu-
coneogenic gene expression. Furthermore, direct analysis
of hepatic insulin signaling demonstrated lower IRS-1 and
IRS-2 expression as well as insulin-stimulated Akt phos-
phorylation in BKS-db hepatocytes. Diminished IRS-1/2
expression has been linked to reduced hepatic insulin
signaling in various obese animal models in comparison to
their lean counterparts (31–34). Thus, our data suggest
that lower IRS-1/2 expression in BKS-db mice results in
relative hepatic insulin resistance in this strain.
Hepatic insulin resistance is a principal component of
type 2 diabetes (35). Decreased insulin sensitivity in liver
leads to elevated hepatic glucose production, hyperinsu-
linemia, increased -cell stress, and hyperglycemia (36).
Animal models indicate that hepatic insulin resistance can
play a primary role in the development of diabetes (37).
For example, diminished insulin signaling due to hepatic
insulin receptor (38) or IRS-1/2 deﬁciency (34,39) causes
hyperglycemia. In line with these studies, we propose that
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to the diabetes-susceptible phenotype of this strain.
What are the metabolic consequences of hepatic insulin
resistance in BKS-db mice? Although we did not directly
demonstrate it in our study, hepatic glucose output is
expected to be higher in BKS-db mice than in B6-db mice.
Diminished insulin signaling in BKS-db liver results in
impaired suppression of gluconeogenic gene expression
and likely elevated glycogenolysis, consistent with lower
hepatic glycogen content observed in this strain. Another
relevant ﬁnding is markedly reduced lipogenic capacity in
the BKS-db liver. It has been proposed that active lipogen-
esis reduces fuel partitioning into the gluconeogenic path-
way, thereby reducing the rate of glucose production at
the substrate level (40). Thus, reduced lipogenesis result-
ing from proximal defects in insulin signaling in BKS-db
mice may contribute to elevated gluconeogenesis, in-
creased -cell stress, and the development of diabetes in
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1622 DIABETES, VOL. 59, JULY 2010 diabetes.diabetesjournals.orgthis strain. Consistent with this hypothesis, decreased
hepatic lipogenesis and steatosis are also associated with
diabetes susceptibility in the obese BTBR-ob (40), lipoatro-
phic FVB-AZIP (41), and liver-speciﬁc Ppar	 knockout
mouse models (42). Moreover, increased hepatic lipogen-
esis and steatosis achieved by overexpressing Srebp1c
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(46) markedly improve glycemia in diabetic mice.
In addition to -cells and liver, metabolic abnormalities
in other tissues may also contribute to the development of
diabetes in BKS-db mice. For example, our results suggest
that low LPL activity in BKS-db adipose tissue is associ-
ated with reduced clearance and elevated levels of plasma
TG, which may inﬂict lipotoxic stress in -cells (47).
Further studies will be needed to address the potential
contribution of adipose tissue to the diabetic phenotype.
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